Immunotherapy: Combined immunotherapy-a new standard in metastatic melanoma?

Nature Reviews Clinical Oncology

Volumn 12, Issue 8, 2015, Pages 439-440

  Hauschild, Axel ^a   Garbe, Claus ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GLYCOPROTEIN GP 100; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TALIMOGENE LAHERPAREPVEC; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CUTANEOUS MELANOMA; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; LONG TERM SURVIVAL; MAINTENANCE THERAPY; METASTATIC MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; SHORT SURVEY; SKIN DISEASE; SURVIVAL RATE; TUMOR VOLUME; FEMALE; MALE; MELANOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MELANOMA;

EID: 84938211509     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.118     Document Type: Short Survey

References (10)

1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
2. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
3. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
4. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. https://dx.doi.org/10.1056/NEJMoa1503093.
5. Das, R. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194, 950-959 (2015).
6. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
7. Chapman, P. B., D'Angelo, S. P. & Wolchok, J. D. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N. Engl. J. Med. 372, 2073-2074 (2015).
8. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. https://dx.doi.org/10.1200/JCO.2014.59.4358.
9. Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225-1231 (2013).
10. Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. https://dx.doi.org/10.1056/NEJMoa1504030.